We are live on
!
Find out more
AC
Ascend Capital Portfolio holdings
AUM
$1.99B
1-Year Est. Return
10.36%
This Fund
S&P 500
This Quarter
Est. Return
+5.95%
1 Year Est. Return
+10.36%
3 Year Est. Return
+56.79%
5 Year Est. Return
+86.43%
10 Year Est. Return
–
AUM
$2.65B
AUM Growth
+$502M
(+23%)
Cap. Flow
+$127M
Cap. Flow
% of AUM
4.8%
Top 10 Holdings %
Top 10 Hldgs %
26.96%
Holding
215
New
70
Increased
41
Reduced
38
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Host Hotels & Resorts
HST
|
+$61.6M |
| 2 |
Puma Biotechnology
PBYI
|
+$61.1M |
| 3 |
Prudential Financial
PRU
|
+$61M |
| 4 |
Viatris
VTRS
|
+$49.3M |
| 5 |
ANDV
Andeavor
ANDV
|
+$49.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MetLife
MET
|
+$53.9M |
| 2 |
Tapestry
TPR
|
+$32.5M |
| 3 |
Pfizer
PFE
|
+$32.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$30.7M |
| 5 |
Kraft Heinz
KHC
|
+$30.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 14.41% |
| 2 | Healthcare | 14.35% |
| 3 | Technology | 11.67% |
| 4 | Energy | 8.22% |
| 5 | Materials | 7.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOMX
126
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.22M | 0.08% |
+399,186
| New | +$2.06M |
|
|
MNK
127
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $2.2M | 0.08% |
58,999
-683,660
| -92% | -$27.2M |
|
|
MASI
128
DELISTED
Masimo
MASI
| $2.19M | 0.08% |
+25,315
| New | +$2.24M |
|
|
FPRX
129
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $2.07M | 0.08% |
+50,630
| New | +$1.59M |
|
|
CMRX
130
DELISTED
Chimerix, Inc.
CMRX
| $1.86M | 0.07% |
+355,353
| New | +$1.75M |
|
131
Netflix
NFLX
$307B
| $1.83M | 0.07% |
+100,880
| New | +$1.76M |
|
|
WRK
132
DELISTED
WestRock Company
WRK
| $1.74M | 0.07% |
+30,568
| New | +$1.75M |
|
133
AnaptysBio
ANAB
$1.54B
| $1.55M | 0.06% |
+44,375
| New | +$1.2M |
|
134
Howard Hughes
HHH
$3.94B
| $1.43M | 0.05% |
+12,693
| New | +$1.45M |
|
|
ARAV
135
DELISTED
Aravive, Inc. Common Stock
ARAV
| $1.29M | 0.05% |
+87,738
| New | +$8.85M |
|
|
SEE
136
DELISTED
Sealed Air
SEE
| $1.15M | 0.04% |
26,837
-181,720
| -87% | -$8.05M |
|
137
Veracyte
VCYT
$4.45B
| $1.08M | 0.04% |
+123,276
| New | +$1M |
|
|
KDNY
138
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.08M | 0.04% |
+20,252
| New | +$1.2M |
|
139
Take-Two Interactive
TTWO
$46.1B
| $1.03M | 0.04% |
+10,126
| New | +$907K |
|
140
Rigel Pharmaceuticals
RIGL
$723M
| $1.02M | 0.04% |
+40,252
| New | +$979K |
|
141
BioMarin Pharmaceuticals
BMRN
$11.9B
| $943K | 0.04% |
10,126
-151,508
| -94% | -$13.4M |
|
142
Viking Therapeutics
VKTX
$3.88B
| $932K | 0.04% |
+488,208
| New | +$554K |
|
|
OXFD
143
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $868K | 0.03% |
+51,655
| New | +$841K |
|
144
Pentair
PNR
$10.8B
| $681K | 0.03% |
14,927
-93
| -0.6% | -$4K |
|
145
Ashland
ASH
$3.34B
| $663K | 0.03% |
10,126
-72,591
| -88% | -$4.63M |
|
|
SWN
146
DELISTED
Southwestern Energy Company
SWN
| $564K | 0.02% |
92,327
-126,589
| -58% | -$717K |
|
|
NXEOW
147
DELISTED
Nexeo Solutions, Inc. Warrant
NXEOW
| $557K | 0.02% |
1,265,363
-6,900
| -0.5% | -$3.41K |
|
148
Methanex
MEOH
$4.23B
| $510K | 0.02% |
10,126
-46,364
| -82% | -$2.18M |
|
149
Forte Biosciences
FBRX
$1.57B
| $464K | 0.02% |
+99
| New | +$441K |
|
|
FRC
150
DELISTED
First Republic Bank
FRC
| $454K | 0.02% |
+4,358
| New | +$433K |
|
Similar funds
MWAC
TP
PC
RW
TBC
BWCA
AC
GCM
Ascend Capital's Q3 2017 Portfolio in Review
As of Q3 2017, Ascend Capital held 215 positions worth $2.65B, up 23% from $2.15B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Ascend Capital deployed $127M of net new capital in Q3 2017, opening 70 new positions and adding to 41 existing holdings. Its largest new stake was Host Hotels & Resorts: 3,386,281 shares worth $62.6M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 14% of assets, down from 15% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was MetLife, an estimated $53.9M trimmed.
- Ascend Capital's largest Q3 2017 buy was Host Hotels & Resorts: 3,386,281 shares worth $62.6M.
- Ascend Capital added most to Puma Biotechnology in Q3 2017, an estimated $61.1M increase.
- Ascend Capital's biggest Q3 2017 reduction was MetLife, cutting an estimated $53.9M.
- Ascend Capital fully exited Tapestry in Q3 2017, selling an estimated $32.5M.
- Ascend Capital's ten largest holdings make up 27% of its $2.65B portfolio in Q3 2017.
- Ascend Capital opened 70 new positions and closed 54 in Q3 2017.
- Ascend Capital's portfolio value rose 23% quarter-over-quarter to $2.65B.
Based on Ascend Capital's 13F filing for Q3 2017, filed 13 Nov 2017.